Send to

Choose Destination
Cancer Biochem Biophys. 1988 Nov;10(2):91-106.

Identification of nanopeptide from HTLV-III, ARV-2 and LAVBRU envelope gp120 determining binding to T4 cell surface protein.

Author information

Laboratory for Multidisciplinary Research RA 180/2, Boris Kidric Institute, Beograd, Yugoslavia.


The information contained in the primary structure of HIV envelope gp120 determining its biological activity, was analyzed by the use of the informational spectrum method. The parameter determining the interaction between gp120 and T4 cell-surface protein was defined. On the basis of this data in the conserved region of gp120 from HTLV-III, LAVBRU and ARV-2, a nanopeptide NAKTIIVQL was identified as a potential binding domain which could be used as a component of an effective therapeutic agent or as a vaccine component.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center